TREATMENT OF OBESITY WITH SGLT–2: OUR RESULTS

Abstract

Abstract SGLT–2 inhibitors were indicated to be able to reduce the weight of diabetic patients for around 4 kilograms. We investigated the possibility to reduce the weight of non–diabetic patients using SGLT–2. Materials and Methods A continuous series of 402 patients were enrolled in a prospective analysis. All patients started a therapy with SGLT–2 inhibitor for a cardiological (80%) or nephrological disease (20%). The 54% used dapagliflozin while the 46% used empagliflozin. In all patients affected by chronic heart failure the SGLT–2 – Inhibitor was added to optimal medical therapy without new symptoms in ambulatory. In nephrological patients the drug was added after a complete stabilization of disease. The recruitment period was long 6 months. After the recruitment the patient was follow for other 6 month. At the end of the follow–up, we evaluated the weight lost. The result was evaluated by an electrical balance, that was the same for all evaluations. The data was collected in excel and analysed by the Q–R–Calc program. Results The mean age of patients was 63 age, 54% female. None was diabetic patients. Hypertension was present in 73%, hypercholesterolemia in 43%. 11% was smokers. 94% were Caucasian patients. The mean of Weight was 75 kg at the first control. The mean height 174 cm. All patients performed a cardiological o nephrological control in which the medical doctor prescribed SGLT–2 inhibitor on top the optical medical therapy. All patients that presented during this control some causes of instability were excluded from the analysis. 90% of patients assumed RAAS inhibitors (ARNI 23%), 81% betablockers, 54% diuretics, 68% MRA. About the subtype of heart failure 60% was HFpEF and 40% HFrEF. The mean GFR of nephrological patients was 31 l/min. After 6 month the mean weight loss was 5,2 kgs with a standard deviation of 3,1 kgs. The reduction of weight was 6.6% of the initial weight. No statistical differences were evaluated comparing empagliflozin and dapagliflozin. Conclusion The SGLT–2 inhibitor in non–diabetic patients was. able to determinate a weight lost of 6.6% (mean 5,2).